Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
Completed Initial Public Offering Raising
Submitted New Drug Application to
“During the third quarter of 2017, Kala strengthened its financial
position by closing a successful initial public offering resulting in
gross proceeds of
Q3 and Recent Corporate Highlights
-
Completed initial public offering in July of 6,900,000 shares
of common stock, including the underwriters’ exercise in full of their
option to purchase an additional 900,000 shares, at the public
offering price of $15.00 per share. The exercise of the underwriters’
option brought the amount of gross proceeds raised in the offering to
approximately $103.5 million, or
$94.1 million in net proceeds after underwriting discounts, commissions and expenses of the offering. - Submitted New Drug Application (NDA) for INVELTYS in October for the treatment of inflammation and pain in patients who have undergone ocular surgery. The NDA submission is supported by positive data from two Phase 3 trials. If approved, Kala expects INVELTYS would be the first twice-daily ocular corticosteroid indicated for the treatment of post-operative ocular inflammation and pain.
-
Strengthened Board of Directors in October with the appointment
of Mr.
Andrew I. Koven , who has served as President and Chief Business Officer at Aralez Pharmaceuticals Inc., since 2016 and held the same position in 2015 at POZEN Inc., where he was instrumental in negotiating a merger with Tribute Pharmaceuticals Canada Inc. to create Aralez Pharmaceuticals. Prior to joining POZEN, Mr. Koven was Chief Administrative Officer, General Counsel and Corporate Secretary at Auxilium Pharmaceuticals Inc.
Upcoming Milestones
-
Top-line results from the Phase 3 clinical program for KPI-121 0.25%
in patients with dry eye disease are expected by the end of 2017.
KPI-121 0.25% is our product candidate for the temporary relief of the
signs and symptoms of dry eye disease utilizing a two-week course of
therapy. Assuming positive results from these trials, the Company
anticipates submitting an NDA in the first half of 2018. If approved,
KPI-121 0.25% could be the first
FDA -approved product for the short-term treatment of dry eye disease.
Third Quarter 2017 Financial Results
-
Cash Position: As of
September 30, 2017 , Kala had cash of$122.0 million compared to$45.5 million as ofDecember 31, 2016 . Cash as ofDecember 31, 2016 did not include net proceeds of approximately$94.1 million from the Company’s initial public offering inJuly 2017 or the proceeds from the draw of the Company’s debt facility of$10.0 million inSeptember 2017 . Kala expects that its existing cash on hand will enable it to fund operations through the second quarter of 2019. -
R&D Expenses: For the quarter ended
September 30, 2017 , research and development expenses were$7.0 million compared to$8.3 million for the same period in 2016. The decrease in research and development expenses is primarily due to a decrease in costs associated with our two Phase 3 clinical trials of KPI-121 0.25% for the treatment of dry eye disease and the completion of our Phase 3 clinical trial of INVELTYS for the treatment of inflammation and pain following ocular surgery in the first half of 2017. -
G&A Expenses: General and administrative expenses for the
quarter ended
September 30, 2017 were$2.5 million compared to$1.5 million for the same period in 2016. The increase in G&A expenses is primarily attributable to an increase in personnel costs and professional fees associated with operating as a public company. -
Operating Loss: Loss from operations for the quarter ended
September 30, 2017 was$9.5 million compared to$9.7 million for the same period in 2016. -
Net Loss: Net loss was
$10.2 million , or$0.56 per share, for the three months endedSeptember 30, 2017 , compared to a net loss of$9.7 million or$8.18 per share, for the same period in 2016.
About INVELTYS™ (KPI-121 1%)
INVELTYS™ (KPI-121 1%) is a
twice-a-day corticosteroid for the treatment of inflammation and pain
following ocular surgery. INVELTYS utilizes Kala’s proprietary
mucus-penetrating particle (MPP) technology to enhance penetration into
target tissues of the eye. In pre-clinical studies, MPP technology
increased delivery of a corticosteroid into ocular tissues more than
three-fold by facilitating penetration through the tear film mucus.
INVELTYS has successfully completed two Phase 3 clinical trials and
achieved statistical significance for both primary efficacy endpoints in
both trials. Kala believes INVELTYS has a favorable treatment profile
compared to the standard of care for the treatment of inflammation and
pain following ocular surgery, due to its twice-a-day dosing regimen and
rapid onset of relief. In each of these trials, INVELTYS was well
tolerated with no treatment-related serious adverse events observed.
About KPI-121 0.25%
Kala is developing KPI-121 0.25% for the
temporary relief of the signs and symptoms of dry eye disease utilizing
a two-week course of therapy administered four times a day. Dry eye
disease is a chronic, episodic, multifactorial disease affecting the
tears and ocular surface that can result in tear film instability,
inflammation, discomfort, visual disturbance and ocular surface damage.
KPI-121 0.25% utilizes Kala’s MPP technology to enhance penetration into
target tissue of the eye. In preclinical studies, MPP technology
increased delivery of a corticosteroid into ocular tissues more than
three-fold by facilitating penetration through the tear film mucus. Kala
believes that KPI-121 0.25%’s broad mechanism of action, rapid onset of
relief of both signs and symptoms, favorable tolerability profile and
potential to be complementary to existing therapies, could result in a
favorable profile for the management of dry eye flares and other dry eye
associated conditions that would benefit from temporary relief of dry
eye signs and symptoms. Following the achievement of successful results
in a Phase 2 trial, Kala is currently evaluating KPI-121 0.25% in two
Phase 3 clinical trials in patients with dry eye disease. If approved,
KPI-121 0.25% could be the first
About Kala Pharmaceuticals, Inc.
Kala is a
biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates. The product candidates are INVELTYS™ (KPI-121 1%)
for the treatment of inflammation and pain following ocular surgery, for
which we have submitted a NDA, and KPI-121 0.25% for the temporary
relief of the signs and symptoms of dry eye disease, currently in Phase
3 clinical development.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, that involve substantial risks and
uncertainties including statements regarding the development and
regulatory status of the company's product candidates, including INVELTYSTM
(KPI-121 1%) for the treatment of inflammation and pain following ocular
surgery and KPI-121 0.25% for the temporary relief of the signs and
symptoms of dry eye disease. All statements, other than statements of
historical facts, contained in this press release, including statements
regarding our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. The Company may not actually achieve
the plans, intentions or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on such
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in the
forward-looking statements as a result of various risks and
uncertainties including, but not limited to: whether our submitted NDA
for INVELTYS will be accepted for filing and approved; uncertainties
inherent in the availability and timing of data from ongoing clinical
trials; whether the data from our Phase 3 clinical trials of KPI-121
0.25% will warrant submission of an NDA on the timeline expected, or at
all, and whether any such NDA would will be approved; expectations for
regulatory approvals to conduct trials or to market products; whether
the Company’s cash resources will be sufficient to fund the Company’s
foreseeable and unforeseeable operating expenses and capital expenditure
requirements; other matters that could affect the availability or
commercial potential of the Company’s product candidates; and other
important factors, any of which could cause our actual results to differ
from those contained in the forward-looking statements, discussed in the
"Risk Factors" section of the Company’s most recently filed Quarterly
Report on Form 10-Q and other filings the Company makes with the
Kala Pharmaceuticals, Inc. Condensed Balance Sheet Data (In thousands) (Unaudited) |
|||||||||||
2017 | 2016 | ||||||||||
September 30, | December 31, | ||||||||||
Cash | $ | 122,049 | $ | 45,472 | |||||||
Working Capital (1) | 111,751 | 40,080 | |||||||||
Total Assets | 123,691 | 46,329 | |||||||||
Convertible Preferred Stock | - | 118,391 | |||||||||
Total Stockholders’ Equity/(Deficit) | 98,863 | (87,762 | ) |
(1) The Company defines working capital as current assets less current liabilities. See the Company’s condensed financial statements for further details regarding its current assets and current liabilities.
Kala Pharmaceuticals, Inc. Condensed Statement of Operations (In thousands, except share and per share data) (Unaudited) |
|||||||||||||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||
September 30, | September 30, | ||||||||||||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||
Research and development | $ | 7,018 | $ | 8,256 | $ | 23,128 | $ | 18,117 | |||||||||||||||||
General and administrative | 2,516 | 1,491 | 5,607 | 6,356 | |||||||||||||||||||||
Total operating expenses | 9,534 | 9,747 | 28,735 | 24,473 | |||||||||||||||||||||
Loss from operations | (9,534 | ) | (9,747 | ) | (28,735 | ) | (24,473 | ) | |||||||||||||||||
Other income (expense): | |||||||||||||||||||||||||
Interest income | 194 | 60 | 276 | 90 | |||||||||||||||||||||
Interest expense | (212 | ) | (186 | ) | (618 | ) | (566 | ) | |||||||||||||||||
Change in fair value of warrant liability | (623 | ) | 206 | (1,844 | ) | 177 | |||||||||||||||||||
Total other income (expense) | (641 | ) | 80 | (2,186 | ) | (299 | ) | ||||||||||||||||||
Net loss attributable to common stockholders—basic and diluted | $ | (10,175 | ) | $ | (9,667 | ) | $ | (30,921 | ) | $ | (24,772 | ) | |||||||||||||
Net loss per share attributable to common stockholders—basic and diluted | $ | (0.56 | ) | $ | (8.18 | ) | $ | (4.51 | ) | $ | (20.97 | ) | |||||||||||||
Weighted average shares outstanding—basic and diluted | 18,034,278 | 1,181,429 | 6,860,777 | 1,181,429 | |||||||||||||||||||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005565/en/
Source:
MacDougall Biomedical Communications
Cammy Duong, 781-591-3443
cduong@macbiocom.com